134 related articles for article (PubMed ID: 17504528)
1. BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study.
Frank B; Hemminki K; Meindl A; Wappenschmidt B; Sutter C; Kiechle M; Bugert P; Schmutzler RK; Bartram CR; Burwinkel B
BMC Cancer; 2007 May; 7():83. PubMed ID: 17504528
[TBL] [Abstract][Full Text] [Related]
2. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G;
Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
[TBL] [Abstract][Full Text] [Related]
5. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy.
Silvestri V; Rizzolo P; Falchetti M; Zanna I; Masala G; Bianchi S; Palli D; Ottini L
Breast Cancer Res Treat; 2011 Apr; 126(2):539-43. PubMed ID: 21165771
[TBL] [Abstract][Full Text] [Related]
6. Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer.
Ameziane N; van den Ouweland AM; Adank MA; Vijzelaar RN; Errami A; Dorsman JC; Joenje H; Meijers-Heijboer H; Waisfisz Q
Breast Cancer Res Treat; 2009 Dec; 118(3):651-3. PubMed ID: 19504183
[No Abstract] [Full Text] [Related]
7. Fanconi anaemia genes and susceptibility to cancer.
Mathew CG
Oncogene; 2006 Sep; 25(43):5875-84. PubMed ID: 16998502
[TBL] [Abstract][Full Text] [Related]
8. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
Eelen G; Vanden Bempt I; Verlinden L; Drijkoningen M; Smeets A; Neven P; Christiaens MR; Marchal K; Bouillon R; Verstuyf A
Oncogene; 2008 Jul; 27(30):4233-41. PubMed ID: 18345034
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort.
McInerney NM; Miller N; Rowan A; Colleran G; Barclay E; Curran C; Kerin MJ; Tomlinson IP; Sawyer E
Breast Cancer Res Treat; 2010 May; 121(1):203-10. PubMed ID: 19763819
[TBL] [Abstract][Full Text] [Related]
10. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
Levran O; Attwooll C; Henry RT; Milton KL; Neveling K; Rio P; Batish SD; Kalb R; Velleuer E; Barral S; Ott J; Petrini J; Schindler D; Hanenberg H; Auerbach AD
Nat Genet; 2005 Sep; 37(9):931-3. PubMed ID: 16116424
[TBL] [Abstract][Full Text] [Related]
11. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
[TBL] [Abstract][Full Text] [Related]
12. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study.
Burwinkel B; Shanmugam KS; Hemminki K; Meindl A; Schmutzler RK; Sutter C; Wappenschmidt B; Kiechle M; Bartram CR; Frank B
BMC Cancer; 2006 Nov; 6():268. PubMed ID: 17109766
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
15. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N
Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622
[TBL] [Abstract][Full Text] [Related]
16. BCoR-L1 variation and breast cancer.
Lose F; Arnold J; Young DB; Brown CJ; Mann GJ; Pupo GM; ; Khanna KK; Chenevix-Trench G; Spurdle AB
Breast Cancer Res; 2007; 9(4):R54. PubMed ID: 17697391
[TBL] [Abstract][Full Text] [Related]
17. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
18. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
Easton DF; Lesueur F; Decker B; Michailidou K; Li J; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Dennis J; Ahmad J; Thompson ER; Damiola F; Pertesi M; Voegele C; Mebirouk N; Robinot N; Durand G; Forey N; Luben RN; Ahmed S; Aittomäki K; Anton-Culver H; Arndt V; ; Baynes C; Beckman MW; Benitez J; Van Den Berg D; Blot WJ; Bogdanova NV; Bojesen SE; Brenner H; Chang-Claude J; Chia KS; Choi JY; Conroy DM; Cox A; Cross SS; Czene K; Darabi H; Devilee P; Eriksson M; Fasching PA; Figueroa J; Flyger H; Fostira F; García-Closas M; Giles GG; Glendon G; González-Neira A; Guénel P; Haiman CA; Hall P; Hart SN; Hartman M; Hooning MJ; Hsiung CN; Ito H; Jakubowska A; James PA; John EM; Johnson N; Jones M; Kabisch M; Kang D; ; Kosma VM; Kristensen V; Lambrechts D; Li N; ; Lindblom A; Long J; Lophatananon A; Lubinski J; Mannermaa A; Manoukian S; Margolin S; Matsuo K; Meindl A; Mitchell G; Muir K; ; Nevelsteen I; van den Ouweland A; Peterlongo P; Phuah SY; Pylkäs K; Rowley SM; Sangrajrang S; Schmutzler RK; Shen CY; Shu XO; Southey MC; Surowy H; Swerdlow A; Teo SH; Tollenaar RA; Tomlinson I; Torres D; Truong T; Vachon C; Verhoef S; Wong-Brown M; Zheng W; Zheng Y; Nevanlinna H; Scott RJ; Andrulis IL; Wu AH; Hopper JL; Couch FJ; Winqvist R; Burwinkel B; Sawyer EJ; Schmidt MK; Rudolph A; Dörk T; Brauch H; Hamann U; Neuhausen SL; Milne RL; Fletcher O; Pharoah PD; Campbell IG; Dunning AM; Le Calvez-Kelm F; Goldgar DE; Tavtigian SV; Chenevix-Trench G
J Med Genet; 2016 May; 53(5):298-309. PubMed ID: 26921362
[TBL] [Abstract][Full Text] [Related]
19. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.
Palli D; Falchetti M; Masala G; Lupi R; Sera F; Saieva C; D'Amico C; Ceroti M; Rizzolo P; Caligo MA; Zanna I; Ottini L
BMC Cancer; 2007 Sep; 7():170. PubMed ID: 17767707
[TBL] [Abstract][Full Text] [Related]
20. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
